GPX4 inhibitors described in Sonata Therapeutics patent
March 7, 2024
Work at Sonata Therapeutics Inc. has led to the creation of phospholipid hydroperoxide glutathione peroxidase, mitochondrial (PHGPx; GPX4) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.